New Metformin Publication Out!

Just as our summer holidays began, we were able to push one of our latest findings with metformin derivatives out. This paper entitled "Optimizing the structure of repurposed metformin can improve anti-cholinesterase and anti-amyloidogenic effects (link)" was recently published in European Journal of Pharmacology and it revealed the potential inhibitory activity of our metformin sulfonamide derivatives against butyrylcholinesterase (BChE) over acetylcholinesterase (AChE), enzymes that play roles in the progression of the Alzheimer's disease. This was again a collaborative project with our Polish friend Magdalena, and this time it also involved computational modelling to estimate the interactions of the compounds with AChE, done by Tuomo. Anyway, the compounds had synergistic effects with the clinically used AChE inhibitor, donepezil, and they inhibited beta-amyloid (Aβ) aggregation at both early and late stages, proving that metformin derivatives could serve as a dual-action therapy for AD.